Once-daily roflumilast foam significantly improves scalp and body psoriasis in 8 weeks and was well-tolerated in adolescents ...

THE MANAGEMENT of plaque psoriasis has evolved significantly over the past two decades, with biologic treatments becoming ...

Research led by the SKiN Center for Dermatology observed substantial clearance of scalp and body psoriasis and rapid itch ...

Most pediatric cases of psoriasis are mild and get better with treatment. Psoriasis isn't contagious ... It may show up like plaque psoriasis, or it may cause a bright red, weeping rash.

of patients with scalp psoriasis and 77% with genital psoriasis treated with investigational icotrokinra achieved site-specific clear or almost clear skin ...

Researchers reviewed a host of studies investigating diet plans in an effort to guide evidence-based recommendations for ...

Johnson & Johnson (JNJ) posts promising late-stage trial data for plaque psoriasis icotrokinra developed with Protagonist ...

Mild to Moderate Plaque Psoriasis, and Moderate to Severe Psoriasis. These reports include a comprehensive understanding of current treatment practices, emerging drugs, market share of individual ...

campaign designed to celebrate the uniqueness of people living with plaque psoriasis. She’s passionate about encouraging individuals to talk to their dermatologists and find a treatment that is ...

The dosing interval for ixekizumab may be extended in some patients with plaque psoriasis, and switching between biologics may also be considered.

The results of an open-label extension study confirmed the interchangeability of biosimilar CT-917 with reference adalimumab for plaque psoriasis.

In December 2021, the US FDA expanded OTEZLA's approval to include adult patients with mild to moderate plaque psoriasis who are suitable candidates for phototherapy or systemic treatment ...